Yael P Mosse

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. pmc Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
    Clin Cancer Res 22:546-52. 2016
  2. pmc Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 18:6058-64. 2012
  3. pmc Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA Electronic address
    Lancet Oncol 14:472-80. 2013
  4. pmc Integrative genomics identifies LMO1 as a neuroblastoma oncogene
    Kai Wang
    The Center for Applied Genomics, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Nature 469:216-20. 2011
  5. pmc Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity
    Kristopher R Bosse
    Division of Oncology and Center for Childhood Cancer Research, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 72:2068-78. 2012
  6. pmc Copy number variation at 1q21.1 associated with neuroblastoma
    Sharon J Diskin
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, USA
    Nature 459:987-91. 2009
  7. pmc Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci
    Le B Nguyen
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    PLoS Genet 7:e1002026. 2011
  8. pmc Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
    Mario Capasso
    Division of Genetics, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Nat Genet 41:718-23. 2009
  9. pmc Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania 19104 4318, USA
    Genome Res 19:276-83. 2009
  10. pmc Identification of ALK as a major familial neuroblastoma predisposition gene
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nature 455:930-5. 2008

Collaborators

Detail Information

Publications32

  1. pmc Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
    Clin Cancer Res 22:546-52. 2016
    ..This review focuses on the role of ALK in pediatric malignancies, alongside the prospects and challenges associated with the development of effective ALK-inhibition strategies...
  2. pmc Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 18:6058-64. 2012
    ..We conducted a phase I trial in children with refractory/recurrent solid tumors to define the maximum-tolerated dose, toxicities, and pharmacokinetic properties of MLN8237...
  3. pmc Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA Electronic address
    Lancet Oncol 14:472-80. 2013
    ..We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma...
  4. pmc Integrative genomics identifies LMO1 as a neuroblastoma oncogene
    Kai Wang
    The Center for Applied Genomics, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Nature 469:216-20. 2011
    ....
  5. pmc Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity
    Kristopher R Bosse
    Division of Oncology and Center for Childhood Cancer Research, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 72:2068-78. 2012
    ..The interaction of BARD1β with the Aurora family of kinases lends strong support to the ongoing work to develop Aurora kinase inhibitors for clinically aggressive neuroblastoma...
  6. pmc Copy number variation at 1q21.1 associated with neuroblastoma
    Sharon J Diskin
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, USA
    Nature 459:987-91. 2009
    ..These data demonstrate that inherited copy number variation at 1q21.1 is associated with neuroblastoma and implicate a previously unknown neuroblastoma breakpoint family gene in early tumorigenesis of this childhood cancer...
  7. pmc Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci
    Le B Nguyen
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    PLoS Genet 7:e1002026. 2011
    ..2 (P = 4.20 × 10⁻⁷) as being associated with the less aggressive form of the disease. These data demonstrate the importance of robust phenotypic data in GWAS analyses and identify additional susceptibility variants for neuroblastoma...
  8. pmc Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
    Mario Capasso
    Division of Genetics, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Nat Genet 41:718-23. 2009
    ..We also found significant association with known BARD1 nonsynonymous SNPs. These data show that common variation in BARD1 contributes to the etiology of the aggressive and most clinically relevant subset of human neuroblastoma...
  9. pmc Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania 19104 4318, USA
    Genome Res 19:276-83. 2009
    ....
  10. pmc Identification of ALK as a major familial neuroblastoma predisposition gene
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nature 455:930-5. 2008
    ....
  11. pmc Cortical processing of respiratory occlusion stimuli in children with central hypoventilation syndrome
    Jingtao Huang
    The Sleep Center, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Am J Respir Crit Care Med 178:757-64. 2008
    ..The ability of patients with central hypoventilation syndrome (CHS) to produce and process mechanoreceptor signals is unknown...
  12. pmc RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma
    Kristina A Cole
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    Proc Natl Acad Sci U S A 108:3336-41. 2011
    ..These data show the power of a functional RNAi screen to identify tractable therapeutical targets in neuroblastoma and support CHK1 inhibition strategies in this disease...
  13. pmc Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
    Kateryna Krytska
    Division of Oncology and Center for Childhood Cancer Research, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Clin Cancer Res 22:948-60. 2016
    ..Thus, understanding mechanisms of resistance and defining circumvention strategies for the clinic is critical...
  14. ncbi request reprint Chromosome 1p and 11q deletions and outcome in neuroblastoma
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, PA 19104 4318, USA
    N Engl J Med 353:2243-53. 2005
    ..Neuroblastoma is a childhood cancer with considerable morbidity and mortality. Tumor-derived biomarkers may improve risk stratification...
  15. doi request reprint Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project
    Yael P Mosse
    Division of Oncology, Children s Hospital of Philadelphia and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:627-35. 2014
    ..Our goal was to determine if an optimal age cut-off exists that defines indolent disease and if accepted prognostic factors and treatment approaches are applicable to older children...
  16. pmc A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene
    Kristina A Cole
    Division of Oncology, Children s Hospital of Philadelphia, Abramson Pediatric Research Center 902A, 3615 Civic Center Boulevard, Philadelphia, PA 19104 4318, USA
    Mol Cancer Res 6:735-42. 2008
    ..BCL2 and MYCN were identified as miR-34a targets and likely mediators of the tumor suppressor phenotypic effect. These data support miR-34a as a tumor suppressor gene in human neuroblastoma...
  17. pmc The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma
    Nicole R Infarinato
    Division of Oncology and Center for Childhood Cancer Research, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Cancer Discov 6:96-107. 2016
    ..Taken together, these results provide the rationale to move PF-06463922 into clinical trials for treatment of patients with ALK-mutated neuroblastoma...
  18. ncbi request reprint Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression
    Yael P Mosse
    Division of Oncology, Children s Hospital of Philadelphia, and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Genes Chromosomes Cancer 46:936-49. 2007
    ..DNA signature patterns embed important prognostic information in diagnostic neuroblastoma samples, and can identify candidate cancer-related genes...
  19. pmc Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma
    Scott C Bresler
    Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 6059, USA
    Sci Transl Med 3:108ra114. 2011
    ..Thus, this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors...
  20. pmc First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium
    Frank M Balis
    The Children s Hospital of Philadelphia, 3501 Civic Center Blvd, CTRB 4024, Philadelphia, PA, 19104, USA
    Cancer Chemother Pharmacol . 2016
    ..Characterize the pharmacokinetics of oral crizotinib in children with cancer...
  21. pmc ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma
    Scott C Bresler
    Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA Graduate Group in Biochemistry and Molecular Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA Medical Scientist Training Program, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
    Cancer Cell 26:682-94. 2014
    ..Our studies identify ALK genomic status as a clinically important therapeutic stratification tool in neuroblastoma and will allow tailoring of ALK-targeted therapy to specific mutations...
  22. doi request reprint Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma
    Kelsey Johnson
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 57:1124-9. 2011
    ..The goal of this study was to determine the safety and efficacy of early (<100 days) second (131) I-MIBG treatment following an effective initial treatment...
  23. pmc Chromosome 6p22 locus associated with clinically aggressive neuroblastoma
    John M Maris
    Division of Oncology and the Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    N Engl J Med 358:2585-93. 2008
    ..Neuroblastoma is a malignant condition of the developing sympathetic nervous system that most commonly affects young children and is often lethal. Its cause is not known...
  24. ncbi request reprint Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13
    John M Maris
    Department of Pediatrics, University of Pennsylvania School of Medicine and Children s Hospital of Philadelphia, Abramson Pediatric Research Center, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 62:6651-8. 2002
    ..Taken together, these data suggest that a hereditary neuroblastoma predisposition gene (HNB1) is located at 16p12-13 and that disruption of this gene may contribute to the pathogenesis of nonfamilial neuroblastomas...
  25. doi request reprint Inhibition of ALK signaling for cancer therapy
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 4318, USA
    Clin Cancer Res 15:5609-14. 2009
    ..The identification of the downstream effector pathways controlled by ALK should pave the way for the rational design of ALK-inhibition therapies for the treatment of a subset of human cancers that harbor ALK aberrations...
  26. pmc STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments
    Sharon J Diskin
    Division of Oncology, Children s Hospital of Philadelphia, Pennsylvania 19104, USA
    Genome Res 16:1149-58. 2006
    ..We conclude that STAC is a powerful tool for identifying nonrandom genomic amplifications and deletions across multiple experiments. A Java version of STAC is freely available for download at http://cbil.upenn.edu/STAC...
  27. pmc Targeting ALK in neuroblastoma--preclinical and clinical advancements
    Erica L Carpenter
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Nat Rev Clin Oncol 9:391-9. 2012
    ....
  28. doi request reprint Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143, USA
    Clin Cancer Res 18:2679-86. 2012
    ..Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG together with fixed doses of vincristine and irinotecan...
  29. pmc Effect of sleep stage on breathing in children with central hypoventilation
    Jingtao Huang
    Sleep Center, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Appl Physiol (1985) 105:44-53. 2008
    ..The hypoventilation in CHS is more severe during NREM than REM sleep. We speculate that this may be due to increased excitatory inputs to the respiratory system during REM sleep...
  30. pmc Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells
    Erica L Carpenter
    Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
    Front Oncol 4:201. 2014
    ..These findings demonstrate a novel, non-invasive, and adaptable method for the capture and genetic analysis of single tumor cells from cancer patients...
  31. ncbi request reprint Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era
    Yael P Mosse
    Division of Oncology, Children s Hospital of Philadelphia, Abramson Pediatric Research Center 902A, 3615 Civic Center Blvd, Philadelphia, PA 19104 4318, USA
    Cancer Lett 228:83-90. 2005
    ....
  32. pmc Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome
    Olivia M Padovan-Merhar
    Children s Hospital of Philadelphia and The University of Pennsylvania, Philadelphia, PA, United States of America
    PLoS Genet 12:e1006501. 2016
    ..However, it will be necessary to conduct prospective clinical trials that match sequencing results to targeted therapeutic intervention to determine if cancer genomic profiling improves patient outcomes...